Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-02-10 23:04Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. is facing a risk of being delisted due to negative net profit and insufficient revenue as per the Shenzhen Stock Exchange regulations [2][3]. Group 1: Delisting Risk Announcement - The company announced on April 29, 2025, that its stock would be subject to delisting risk warning starting April 30, 2025, due to a negative net profit and revenue below 300 million yuan for the fiscal year 2024 [2][3]. - According to the Shenzhen Stock Exchange's listing rules, if the company continues to meet the criteria for delisting in the following fiscal year, its stock may be terminated from listing [3][11]. Group 2: Financial Performance Indicators - The audited net profit for the fiscal year 2024 was reported as negative, and the operating revenue was below 300 million yuan, triggering the delisting risk warning [3][4]. - The company projected a net profit (excluding non-recurring gains and losses) for 2025 to be between -46 million yuan and -33 million yuan, with expected operating revenue between 330 million yuan and 350 million yuan [11]. Group 3: Compliance and Disclosure Obligations - The company is required to disclose risk warning announcements every ten trading days until the annual report is released, following the initial risk warning announcement [2][11]. - The company will adhere to the information disclosure obligations as stipulated by the Shenzhen Stock Exchange, with designated media for announcements including Securities Times and China Securities Journal [11].